Patients
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Hua MedicineChina - Shanghai
2 programsEmpagliflozinPHASE_1Small Molecule1 trial
SitagliptinPHASE_1Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Hua MedicineEmpagliflozin
Hua MedicineSitagliptin
UNION therapeuticsSteroid-eluting stent implant
Clinical Trials (3)
Total enrollment: 71 patients across 3 trials
Drug Interaction Study Between Dorzagliatin and Empagliflozin
Start: Apr 2019Est. completion: Mar 202016 patients
Phase 1Completed
Drug Interaction Study Between Dorzagliatin and Sitagliptin
Start: Jan 2019Est. completion: Aug 201915 patients
Phase 1Completed
The Effects of Steroid-eluting Stent Implant for the Treatment of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
Start: Oct 2018Est. completion: Oct 202140 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.